公开(公告)号：US06855461B2

公开(公告)日：2005-02-15

申请号：US10073678

申请日：2002-02-11

申请人： Christina Lampe-Onnerud ,  Per Onnerud ,  Dmitri Novikov ,  Jie Shi ,  Richard Chamberlain ,  Tomoyoshi Koizumi ,  Aisaku Nagai

发明人： Christina Lampe-Onnerud ,  Per Onnerud ,  Dmitri Novikov ,  Jie Shi ,  Richard Chamberlain ,  Tomoyoshi Koizumi ,  Aisaku Nagai

IPC分类号： C01G53/00 ,  C01B35/10 ,  C01G23/04 ,  C01G31/02 ,  C01G45/12 ,  C01G49/02 ,  C01G51/04 ,  C01G53/04 ,  H01M2/02 ,  H01M4/131 ,  H01M4/525 ,  H01M10/052 ,  H01M4/58

CPC分类号： C01G53/50 ,  C01G53/66 ,  C01P2002/77 ,  C01P2006/40 ,  H01M4/131 ,  H01M4/525 ,  H01M4/622 ,  H01M4/625 ,  H01M10/052

摘要： A crystal which can be employed as the active material of a lithium-based battery has an empirical formula of Lix1A2Ni1-y-zCoyBzOa, wherein “x1” is greater than about 0.1 and equal to or less than about 1.3, “x2,” “y” and “z” each is greater than about 0.0 and equal to or less than about 0.2, “a” is greater than about 1.5 and less than about 2.1, “A” is at least one element selected from the group consisting of barium, magnesium, calcium and strontium and “B” is at least one element selected from the group consisting of boron, aluminum, gallium, manganese, titanium, vanadium and zirconium. A method includes combining lithium, nickel, cobalt and at least one element “A” selected from the group consisting of barium, magnesium, calcium and strontium, has at least one element “B” selected from the group consisting of boron, aluminum, gallium, manganese, titanium, vanadium and zirconium, in the presence of oxygen, wherein the combined components have the relative ratio of Lix1:Ax2:Ni1-y-z:Coy:Bz, wherein “x1,” “x2,” “y” and “z” have the values given for the empirical formula shown above.

摘要翻译： 可以用作锂基电池的活性材料的晶体具有Lix1A2Ni1-y-zCoyBzOa的经验式，其中“x1”大于约0.1且等于或小于约1.3，“x2”，“ y“和”z“各自大于约0.0且等于或小于约0.2，”a“大于约1.5且小于约2.1，”A“是选自由以下组成的组中的至少一种元素：钡 ，镁，钙和锶，“B”是选自硼，铝，镓，锰，钛，钒和锆中的至少一种元素。 一种方法包括组合锂，镍，钴和至少一种选自钡，镁，钙和锶的元素“A”，具有至少一种选自硼，铝，镓的元素“B” ，锰，钛，钒和锆，其中组合成分具有Lix1：Ax2:Ni1-yz:Coy:Bz的相对比例，其中“x1”，“x2”，“y”和“ z“具有上述经验公式给出的值。

公开(公告)号：US20030118581A1

公开(公告)日：2003-06-26

申请号：US10267795

申请日：2002-10-10

申请人： KUREHA CHEMICAL INDUSTRY CO., LTD.

发明人： Naohiro Sonobe ,  Michihito Ise ,  Susumu Morimoto ,  Hideyuki Yamato ,  Satoshi Mitsuhashi ,  Haruhisa Hayashi

IPC分类号： A61K033/44

CPC分类号： A61K33/44 ,  A61K9/143

摘要： An adsorbent for an oral administration, comprising a porous spherical carbonaceous substance wherein a diameter is 0.01 to 1 mm, a specific surface area determined by a BET method is 700 m2/g or more, a volume of pores having a pore diameter of 20 to 15000 nm is from not less than 0.04 mL/g to less than 0.10 mL/g, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 1.00 meq/g, is disclosed.

摘要翻译： 一种用于口服给药的吸附剂，其包含直径为0.01至1mm的多孔球形碳质物质，通过BET法测定的比表面积为700m 2 / g以上，孔径为20〜 15000nm从不小于0.04mL / g至小于0.10mL / g，酸性基团的总量为0.30〜1.20meq / g，碱性基团的总量为0.20〜1.00meq / g，公开了 。

公开(公告)号：US20020192552A1

公开(公告)日：2002-12-19

申请号：US10073674

申请日：2002-02-11

申请人： Kureha Chemical Industry Co., Ltd.

发明人： Christina Lampe-Onnerud ,  Per Onnerud ,  Jie Shi ,  Sharon Dalton ,  Tomoyoshi Koizumi ,  Aisaku Nagai

IPC分类号： H01M004/52 ,  H01M004/50

CPC分类号： H01M4/525 ,  H01M4/0471 ,  H01M4/131 ,  H01M4/1391 ,  H01M4/366 ,  H01M10/052

摘要： A composition suitable for use as a cathode material of a lithium battery includes a core material having an empirical formula LixMnullzNi1nullyMnullyO2. nullxnull is equal to or greater than about 0.1 and equal to or less than about 1.3. nullynull is greater than about 0.0 and equal to or less than about 0.5. nullznull is greater than about 0.0 and equal to or less than about 0.2. Mnull is at least one member of the group consisting of sodium, potassium, nickel, calcium, magnesium and strontium. Mnull is at least one member of the group consisting of cobalt, iron, manganese, chromium, vanadium, titanium, magnesium, silicon, boron, aluminum and gallium. A coating on the core has a greater ratio of cobalt to nickel than the core. The coating and, optionally, the core can be a material having an empirical formula Lix1Ax2Ni1nully1nullz1Coy1Bz1Oa. nullx1null is greater than about 0.1 and equal to or less than about 1.3. nullx2,null nully1null and nullz1null each is greater than about 0.0 and equal to or less than about 0.2. nullanull is greater than 1.5 and less than about 2.1. nullAnull is at least one element selected from the group consisting of barium, magnesium, calcium and strontium. nullBnull is at least one element selected from the group consisting of boron, aluminum, gallium, manganese, titanium, vanadium and zirconium.

摘要翻译： 适合用作锂电池阴极材料的组合物包括具有经验式LixM'zNi1-yM''O2的芯材。 “x”等于或大于约0.1且等于或小于约1.3。 “y”大于约0.0且等于或小于约0.5。 “z”大于约0.0且等于或小于约0.2。 M'是由钠，钾，镍，钙，镁和锶组成的组中的至少一个成员。 M“是由钴，铁，锰，铬，钒，钛，镁，硅，硼，铝和镓组成的组中的至少一个。 芯上的涂层具有比芯更大的钴与镍的比例。 涂层和任选的芯可以是具有经验式Lix1Ax2Ni1-y1-z1Coy1Bz10a的材料。 “x1”大于约0.1且等于或小于约1.3。 “x2”，“y1”和“z1”各自大于约0.0且等于或小于约0.2。 “a”大于1.5且小于约2.1。 “A”是选自钡，镁，钙和锶中的至少一种元素。 “B”是选自硼，铝，镓，锰，钛，钒和锆中的至少一种元素。

公开(公告)号：US5932575A

公开(公告)日：1999-08-03

申请号：US991411

申请日：1997-12-16

申请人： Mikiro Yanaka ,  Fuyuhiko Nishijima ,  Mikio Sugano ,  Hiroshi Takahashi ,  Shigeru Suzuki ,  Hiroyuki Enari ,  Michihito Ise

发明人： Mikiro Yanaka ,  Fuyuhiko Nishijima ,  Mikio Sugano ,  Hiroshi Takahashi ,  Shigeru Suzuki ,  Hiroyuki Enari ,  Michihito Ise

IPC分类号： C07D295/18 ,  A61K31/40 ,  A61K31/44 ,  A61K31/495 ,  A61K31/535 ,  A61K31/5375 ,  A61P9/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07D207/16 ,  C07D207/24 ,  C07D213/79 ,  C07D257/04 ,  C07D295/192 ,  A61K31/445

CPC分类号： C07D213/79 ,  C07D207/16 ,  C07D257/04 ,  C07D295/192

摘要： This invention relates to cardiac diseases improving agents substantially free from antagonistic action to type 1 receptor of angiotensin II which participates to hypotensive action. Particularly, this invention relates to cardiac diseases improving agents composed of effective ingredients of aromatic compounds or pharmacologically acceptable salts thereof shown by below mentioned general formula. ##STR1## (wherein, substituents thereof typically include, R.sup.1, R.sup.4, R.sup.13 representing hydrogen atom, an alkyl group, a haloalkyl group and so forth, R.sup.8 representing --CO--, --SO.sub.2 -- or single bond, R.sup.2 representing a 3-7 membered aliphatic cyclic amino group having at least one nitrogen atom, R.sup.7 representing --CO-- or --SO.sub.2 --, and R.sup.12 representing N-substituted valeramido group.)

摘要翻译： 本发明涉及对参与低血压作用的血管紧张素II的1型受体基本上没有拮抗作用的心脏病改善剂。 特别地，本发明涉及由下述通式所示的芳族化合物的有效成分或其药理学上可接受的盐组成的心脏病改善剂。 （其中，取代基通常包括代表氢原子，烷基，卤代烷基等的R 1，R 4，R 13，R 8表示-CO - ， - SO 2 - 或单键，R 2表示3-7元脂肪族环状 具有至少一个氮原子的氨基，R 7表示-CO-或-SO 2 - ，R 12表示N-取代的戊酰氨基。

公开(公告)号：US5696118A

公开(公告)日：1997-12-09

申请号：US457147

申请日：1995-06-01

申请人： Mikiro Yanaka ,  Fuyuhiko Nishijima ,  Hiroyuki Enari ,  Toshikazu Dewa ,  Toru Yamazaki ,  Michihito Ise

发明人： Mikiro Yanaka ,  Fuyuhiko Nishijima ,  Hiroyuki Enari ,  Toshikazu Dewa ,  Toru Yamazaki ,  Michihito Ise

IPC分类号： C07D213/79 ,  C07D213/81 ,  C07D257/04 ,  C07D295/192 ,  C07D295/26 ,  A61K31/445 ,  A61K31/535

CPC分类号： C07D213/79 ,  C07D213/81 ,  C07D257/04 ,  C07D295/192 ,  C07D295/26

摘要： A benzene derivative of the formula (I): ##STR1## wherein R.sup.1 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -haloalkyl, --NH.sub.2, --NHR.sup.21 ; R.sup.2 is hydroxyl, --OR.sup.22, three- to seven-membered saturated cycloaliphatic amino optionally interrupted by one or more nitrogen, oxygen or sulfur atoms, --NHR.sup.23, --N(R.sup.24).sub.2, --NH.sub.2 ; R.sup.4 is hydrogen, C.sub.1-6 -alkyl, or --C(.dbd.O)R.sup.25 ; R.sup.7 is --CO--, --SO.sub.2 --; R.sup.8 is --CO--, single bond; R.sup.12 is --R.sup.11 --R.sup.5 ; R.sup.11 is --N(R.sup.5)--, --NH--, --O--, --N(R.sup.26)--, --N(C(.dbd.O)R.sup.27)--, --N(C(.dbd.O)NH.sub.2)--, --N(C(.dbd.O)NHR.sup.28)--; R.sup.13 is hydrogen, C.sub.1-6 -alkyl, C.sub.1-6 -haloalkyl, --NHC(.dbd.O)(CH.sub.2).sub.m C.sub.6 H.sub.5, --NHC(.dbd.O)R.sup.29, --NHC(.dbd.O)CH(C.sub.6 H.sub.5).sub.2, --NH.sub.2, --NHR.sup.30, --(CH.sub.2).sub.n C.sub.6 H.sub.5 ; Z is C, CH, N; A is CH, N; R.sup.5 is hydrogen, --CH.sub.2 C.sub.6 H.sub.4 COOH, --CH.sub.2 C.sub.6 H.sub.4 COOR.sup.31, --CH.sub.2 C.sub.6 H.sub.4 OH, --CH.sub.2 C.sub.6 H.sub.4 OR.sup.32, --CH.sub.2 C.sub.6 H.sub.4 NH.sub.2, --CH.sub.2 C.sub.6 H.sub.4 N(R.sup.33).sub.2, --CH.sub.2 C.sub.6 H.sub.4 -azole, --CH.sub.2 C.sub.6 H.sub.4 NHR.sup.34, --CH.sub.2 C.sub.6 H.sub.4 C.sub.6 H.sub.4 R.sup.14 ; R.sup.14 is azole, --COOH; R.sup.21 to R.sup.34 are independently C.sub.1-6 -alkyl or C.sub.1-6 -haloalkyl; m is 0 to 6; n is 0 to 6; t is 0 or 1, with the proviso that when Z is N, R.sup.5 is hydrogen, --CH.sub.2 C.sub.6 H.sub.4 COOH, --CH.sub.2 C.sub.6 H.sub.4 COOR.sup.31, --CH.sub.2 C.sub.6 H.sub.4 OH, --CH.sub.2 C.sub.6 H.sub.4 OR.sup.32, --CH.sub.2 C.sub.6 H.sub.4 NH.sub.2, --CH.sub.2 C.sub.6 H.sub.4 N(R.sup.33).sub.2, --CH.sub.2 C.sub.6 H.sub.4 -azole, or --CH.sub.2 C.sub.6 H.sub.4 NHR.sup.34, or a salt thereof, and a pharmaceutical composition comprising said benzene derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier are disclosed.

摘要翻译： 式（I）的苯衍生物：其中R 1是氢，C 1-6 - 烷基，C 1-6 - 卤代烷基，-NH 2，-NHR 21; R2是羟基，-OR22，任选地被一个或多个氮，氧或硫原子间隔的三至七元饱和脂环族氨基，-NHR 23，-N（R 24）2，-NH 2; R 4是氢，C 1-6 - 烷基或-C（= O）R 25; R 7是-CO - ， - SO 2 - ; R8是-CO-，单键; R12为-R11-R5; R 11是-N（R 5） - ， - NH - ， - O - ， - N（R 26） - ， - N（C（= O）R 27） - ， - N（C（= O）NH 2） （C（= O）NHR 28） - ; R 13是氢，C 1-6 - 烷基，C 1-6 - 卤代烷基，-NHC（= O）（CH 2）m C 6 H 5，-NHC（= O）R 29，-NHC（= O）CH（C 6 H 5）2，-NH 2， -NHR 30， - （CH 2）n C 6 H 5; Z是C，CH，N; A是CH，N; R5是氢，-CH2C6H4COOH，-CH2C6H4COOR31，-CH2C6H4OH，-CH2C6H4OR32，-CH2C6H4NH2，-CH2C6H4N（R33）2，-CH2C6H4-唑，-CH2C6H4NHR34，-CH2C6H4C6H4R14; R14是唑，-COOH; R 21至R 34独立地为C 1-6 - 烷基或C 1-6 - 卤代烷基; m为0〜6; n为0〜6; t为0或1，条件是当Z为N时，R5为氢，-CH2C6H4COOH，-CH2C6H4COOR31，-CH2C6H4OH，-CH2C6H4OR32，-CH2C6H4NH2，-CH2C6H4N（R33）2，-CH2C6H4-唑或-CH2C6H4NHR34， 或其盐，以及包含所述苯衍生物或其药学上可接受的盐和药学上可接受的载体的药物组合物。

公开(公告)号：US5650433A

公开(公告)日：1997-07-22

申请号：US519179

申请日：1995-08-25

申请人： Koju Watanabe ,  Koichi Niimura ,  Kiyonori Umekawa

发明人： Koju Watanabe ,  Koichi Niimura ,  Kiyonori Umekawa

IPC分类号： A61K31/35 ,  A61K31/352 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/7048 ,  A61P29/00 ,  A61P43/00 ,  C07D311/30 ,  C07D311/32 ,  C07H17/07

CPC分类号： A61K31/7048 ,  A61K31/35 ,  A61K31/352 ,  A61K31/70

摘要： A chondroprotective agent comprising a flavonoid compound of the general formula (I): ##STR1## wherein R.sup.1 to R.sup.9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof, or a naturally occurring glycoside thereof is disclosed. The above compound strongly inhibits proteoglycan depletion from the chondrocyte matrix and exhibits a function to protect cartilage, and thus, is extremely effective for the treatment of arthropathy.

摘要翻译： 一种软骨保护剂，其包含通式（I）的类黄酮化合物：其中R 1至R 9独立地为氢原子，羟基或甲氧基，X为单键或双键， 或其立体异构体，或其天然存在的糖苷。 上述化合物强烈地抑制软骨细胞基质中的蛋白多糖消耗，并表现出保护软骨的功能，因此对于治疗关节病是非常有效的。

公开(公告)号：US5643775A

公开(公告)日：1997-07-01

申请号：US406554

申请日：1995-03-20

申请人： Eisaku Takahashi ,  Eiichi Takahashi ,  Kohki Saitoh ,  Toshihiko Wada ,  Yutaka Konai

发明人： Eisaku Takahashi ,  Eiichi Takahashi ,  Kohki Saitoh ,  Toshihiko Wada ,  Yutaka Konai

IPC分类号： C12N9/10 ,  C12P19/12 ,  C12R1/645

CPC分类号： C12N9/1051 ,  C12P19/12

摘要： This invention provides highly thermally stable trehalose phosphorylases. The trehalose phosphorylases of the present invention can be obtained from cultured mixture of microorganisms and are highly thermally stable, and produce .alpha.-D-glucose 1-phosphate and D-glucose by an action on trehalose and an inorganic phosphoric acid or salt thereof, or trehalose by an action on .alpha.-D-glucose 1-phosphate and D-glucose. This invention also relates to the process for the preparation of trehalose phosphorylase, and trehalose or .alpha.-D-glucose 1-phosphate with said trehalose phosphorylase.

摘要翻译： 本发明提供高度热稳定的海藻糖磷酸酶。 本发明的海藻糖磷酸酶可以由培养的微生物混合物获得并且是高度热稳定的，并且通过对海藻糖和无机磷酸或其盐的作用产生α-D-葡萄糖1-磷酸酯和D-葡萄糖，或 通过对α-D-葡萄糖1-磷酸和D-葡萄糖的作用的海藻糖。 本发明还涉及用所述海藻糖磷酸化酶制备海藻糖磷酸化酶，海藻糖或α-D-葡萄糖1-磷酸的方法。

公开(公告)号：US5585381A

公开(公告)日：1996-12-17

申请号：US454629

申请日：1995-05-31

申请人： Mikiro Yanaka ,  Fuyuhiko Nishijima ,  Hiroyuki Enari ,  Michihito Ise

发明人： Mikiro Yanaka ,  Fuyuhiko Nishijima ,  Hiroyuki Enari ,  Michihito Ise

IPC分类号： A61P13/12 ,  C07D239/48 ,  C07D239/50 ,  A61K31/505

CPC分类号： C07D239/48 ,  C07D239/49 ,  C07D239/50

摘要： A pyrimidine derivative of the formula (I): ##STR1## wherein R.sup.1 is a hydrogen atom, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, or --NHR.sup.11 group; R.sup.2 is a hydrogen or halogen atom, alkyl of 1 to 6 carbon atoms, haloalkyl of 1 to 6 carbon atoms, --(CH.sub.2).sub.m C.sub.6 H.sub.5, --NH.sub.2, --NHR.sup.12, --NH(CH.sub.2).sub.n C.sub.6 H.sub.5, --NH(CH.sub.2).sub.p C.sub.6 H.sub.4 --OR.sup.13, --N(R.sup.14)(CH.sub.2).sub.q C.sub.6 H.sub.5, --NHC(.dbd.O)R.sup.15, --NHC(.dbd.O)(CH.sub.2).sub.r C.sub.6 H.sub.5, --NHC(.dbd.O)CH(C.sub.6 H.sub.5).sub.2, --OR.sup.16, or --O(CH.sub.2).sub.s C.sub.6 H.sub.5 group; R.sup.3 is --COOH, --COOR.sup.17, hydroxyl, --OR.sup.18, --NH.sub.2, --N(R.sup.19).sub.2, --NHR.sup.20, azole, or sulfonic acid group; R.sup.11 is alkyl of 1 to 6 carbon atoms or haloalkyl of 1 to 6 carbon atoms; R.sup.12, R.sup.13, R.sup.14, R.sup.15, R.sup.16, R.sup.17, R.sup.18, R.sup.19, and R.sup.20 are independently alkyl of 1 to 6 carbon atoms; m is 0 or an integer of 1 to 6; n is 0 or an integer of 1 to 6; p is 0 or an integer of 1 to 6; q is 0 or an integer of 1 to 6; r is 0 or an integer of 1 to 6; and s is 0 or an integer of 1 to 6, or a salt thereof, and a pharmaceutical composition comprising said pyrimidine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier are disclosed.

摘要翻译： 式（I）的嘧啶衍生物：其中R 1为氢原子，1至6个碳原子的烷基，1至6个碳原子的卤代烷基或-NHR 11基团; R2是氢或卤素原子，1-6个碳原子的烷基，1-6个碳原子的卤代烷基， - （CH2）mC6H5，-NH2，-NHR12，-NH（CH2）nC6H5，-NH（CH2）pC6H4- OR 13，-N（R 14）（CH 2）q C 6 H 5，-NHC（= O）R 15，-NHC（= O）（CH 2）rC 6 H 5，-NHC（= O）CH（C 6 H 5）2，-OR 16或-O CH2）sC6H5组; R3是-COOH，-COOR17，羟基，-OR18，-NH2，-N（R19）2，-NHR20，唑或磺酸基团; R11为1〜6个碳原子的烷基或1〜6个碳原子的卤代烷基; R 12，R 13，R 14，R 15，R 16，R 17，R 18，R 19和R 20独立地为1至6个碳原子的烷基; m为0或1〜6的整数; n为0或1〜6的整数， p为0或1〜6的整数; q为0或1〜6的整数; r为0或1〜6的整数， 和s为0或1〜6的整数，或其盐，以及包含所述嘧啶衍生物或其药学上可接受的盐和药学上可接受的载体的药物组合物。

公开(公告)号：US5569524A

公开(公告)日：1996-10-29

申请号：US163754

申请日：1993-12-07

申请人： Masamichi Akatsu ,  Takeo Higashi ,  Hiromitsu Makita ,  Tomoo Susa ,  Toshiya Mizuno

发明人： Masamichi Akatsu ,  Takeo Higashi ,  Hiromitsu Makita ,  Tomoo Susa ,  Toshiya Mizuno

IPC分类号： B29C65/04 ,  B32B7/12 ,  B32B27/12 ,  B32B27/30 ,  B32B37/00 ,  B32B7/10 ,  B32B27/08

CPC分类号： B32B27/30 ,  B29C65/04 ,  B29K2027/06 ,  B29K2027/16 ,  B29K2033/04 ,  B29K2105/0085 ,  B29K2105/0088 ,  B29L2007/005 ,  B32B2309/105 ,  B32B2459/00 ,  B32B37/00 ,  B32B37/1284 ,  Y10T428/24967 ,  Y10T428/266 ,  Y10T428/2809 ,  Y10T428/3154 ,  Y10T428/3192 ,  Y10T428/31928 ,  Y10T428/31935 ,  Y10T442/387

摘要： A laminated sheet suitable for high-frequency welding comprises a vinylidene fluoride resin layer (A), a bonding layer (B) consisting of a blend of vinylidene fluoride resin and a copolymer resin consisting of methyl methacrylate and alkyl ester of acrylate, whose alkyl group has 3-5 carbon atoms, a base-material layer (C) of vinyl chloride resin bonded to the bonding layer (B), and a base-cloth layer (D) bonded to the base-material layer (C). A bonded laminated sheet obtained by bonding two laminated sheets with high-frequency welding and the application of the bonded laminated sheet to tents are also disclosed.

摘要翻译： 适用于高频焊接的层压片包括偏二氟乙烯树脂层（A），由偏氟乙烯树脂和由甲基丙烯酸甲酯和丙烯酸烷基酯组成的共聚物树脂的共混物组成的粘合层（B），其烷基 具有3-5个碳原子，与粘合层（B）接合的氯乙烯树脂的基材层（C）和与基材层（C）结合的基布层（D）。 还公开了通过将两个高频焊接的层叠片接合并将接合的层叠片施加到帐篷而获得的粘合层叠片。

公开(公告)号：US5455268A

公开(公告)日：1995-10-03

申请号：US204445

申请日：1994-03-02

申请人： Koju Watanabe ,  Koichi Niimura ,  Kiyonori Umekawa

发明人： Koju Watanabe ,  Koichi Niimura ,  Kiyonori Umekawa

IPC分类号： A61K31/37 ,  A61P43/00 ,  C07D311/16 ,  A61K31/35

CPC分类号： A61K31/37 ,  C07D311/16 ,  Y10S514/825

摘要： A pharmaceutical composition comprising a compound of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are, independently, a hydrogen atom, a saturated or unsaturated aliphatic acyl having 2 to 25 carbon atoms or benzoyl group and R.sup.3 is a hydrogen atom or alkyl group, and a pharmaceutically acceptable carrier is disclosed. Further, a novel compound of the general formula (I) wherein R.sup.1 and R.sup.2 are, independently, a hydrogen atom, pivaloyl, capryloyl, lauroyl, palmitoyl, stearoyl, linoleoyl, docosahexaenoyl, or benzoyl group, and R.sup.3 is a hydrogen atom or methyl group, is also disclosed.

摘要翻译： 一种药物组合物，其包含通式（I）的化合物：其中R 1和R 2独立地为氢原子，具有2至25个碳原子的饱和或不饱和脂族酰基或苯甲酰基，R 3为 公开了氢原子或烷基，以及药学上可接受的载体。 此外，通式（I）的新化合物，其中R 1和R 2独立地为氢原子，新戊酰基，辛酰基，月桂酰基，棕榈酰基，硬脂酰基，亚油酰基，二十二碳六烯酰基或苯甲酰基，R 3为氢原子或甲基 ，也被披露。